Introduction
Worldwide, colorectal cancer (CRC) is a leading cause of cancer related deaths 1 . Australia and New Zealand have the highest incidence of CRC with age-standardized rates of 44.8 and 32.2 per 100 000 in men and women, respectively 1 . The lifetime risk of CRC to age 75 years in Australia is 1 in 18 (5.5%) for men and 1 in 26 (3.9%) for women, and is the second most common cause of cancer-related death after lung cancer 2 . One way to reduce the incidence of CRC is to identify high risk individuals in the population and target them for screening and increased surveillance. Lynch syndrome is an autosomal dominant cancer predisposition disorder, defined by the identification of a pathogenic germline mutation in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2 or in EPCAM, a gene upstream of MSH2. MMR gene mutation carriers have a high risk of developing cancers within the large intestine and the endometrium, and also from the urinary tract, pancreas, hepatobiliary tract, stomach, small intestine and ovaries 3 . Up to 6% of all CRCs can be attributed to Lynch syndrome making it the most common hereditary CRC condition 4 . The identification of MMR gene mutation carriers enables appropriate risk management strategies that can improve patient outcomes.
Tumors arising in individuals with a MMR gene mutation demonstrate high levels of microsatellite instability (MSI) secondary to altered DNA MMR mechanisms. Testing tumors for evidence of this MMR deficiency by immunohistochemistry (IHC) is widely used by pathologists to screen for Lynch syndrome 5 . Two population-based studies have previously reported the identification of Lynch syndrome in Australia, one from Victoria in CRC patients diagnosed before 45 years 6 and one from Western Australia in CRC patients diagnosed before 60 years 7 . In this study, we describe the identification of Lynch syndrome in one early-onset CRC cohort and one later onset CRC cohort both derived from Victoria, Australia.
Methods
Study participants. Participants were identified from two different Australian studies: the Australasian Colorectal Cancer Family Registry (ACCFR) and the Melbourne Collaborative Cohort Study (MCCS). In the ACCFR, population-based incident CRC cases were recruited, independent of family history of cancer, in Victoria between 1997 and 2007 8 . Of these, we identified 959 probands with a primary adenocarcinoma of the colon or rectum during two recruitment periods. Phase I recruitment (1997) (1998) (1999) (2000) (2001) included all patients with a CRC diagnosed between 18 and 44 years of age and 50% of patients with CRC diagnosed between the ages of 45-59 years. Phase II recruitment (2001) (2002) (2003) (2004) (2005) (2006) included all patients with a CRC diagnosed between 18 and 49 years of age. A proportion of these cases presented in this study (71 individuals from phase II recruitment) were reported in a previous study 6 . The MCCS is a prospective cohort study of 41, 514 people (17, 045 men and 24, 469 women) recruited between 1990 and 1994 9 . Participants diagnosed with an incident CRC were aged 41-86 years. By 31 December 2009, 1046 participants had a first histopathological diagnosis of invasive adenocarcinoma of the colon or rectum in Victoria following the baseline study visit (a total of 1101 CRCs). A further 25 subjects had a clinical diagnosis only and were not considered as cases. Insufficient sample remained for 50 (5%) tumors, and the sample could not be obtained or was not sent for testing for 181 (17%) of the eligible tumors. In total, data were available for 851 of the eligible tumors from 826 of the MCCS participants.
Written informed consent was obtained from all participants to collect a blood sample and tumor pathology materials. The study protocols were approved by Human Research Ethics Committees at the University of Melbourne (ACCFR) and the Cancer Council Victoria (MCCS).
Family history of colorectal cancer and extra-colonic cancers. For the ACCFR, information on personal and family history of CRC and other cancers in firstand/or second-degree relatives was obtained from completion of baseline and follow-up questionnaires completed at recruitment and five yearly thereafter, respectively. Cancers were verified, where possible using pathology reports, medical records, cancer registry reports, and/or death certificates 8 . Information on cancer family history was used to determine if the proband's family history met Amsterdam I or II criteria or the revised Bethesda guidelines 10, 11 . Information on family history of CRC was not available for the MCCS probands.
Pathology review. Primary CRC tissue was available for 813 of the probands from the ACCFR Jeremy Jass Memorial Tissue Bank and 851 from the MCCS for standardized pathological review and molecular characterization 12 . Tumors from the ileo-caecal junction through the caecum, ascending colon, hepatic flexure, and transverse colon were grouped as right-sided (proximal). Tumors from the splenic flexure, descending, sigmoid colon, and recto-sigmoid junction were classified as left-sided (distal); tumors from the rectum were considered as a third distinct group. Tumor, nodes and metastasis (TNM) stage was derived from the pathological stage of the tumor and of the lymph node status, and the clinical metastatic stage.
DNA mismatch repair deficiency and molecular testing. MMR deficiency was determined primarily by IHC staining for the four MMR proteins as previously described 13, 14 . MSI was determined from a 10-marker panel in 794 tumors collected from the MCCS and for 555 tumors collected from the ACCFR (predominantly Phase I recruited participants and for CRCs showing loss of MMR protein expression), as previously described 5, 13 . Tumors were categorized as: (1) methylation of the MLH1 promoter region using the MethyLight assay as previously described 15, 16 . All CRCs were tested for the BRAF V600E somatic mutation using a fluorescent allele-specific polymerase chain reaction assay as previously described 17 .
Germline mutation testing. Germline MMR gene mutation testing was performed using Sanger sequencing and Multiplex Ligation Dependent Probe Amplification, including testing for 3′ deletions in EPCAM as previously described 8, 14, 15, 18 . For the ACCFR, the following probands were tested: (1) MMR-deficient CRCs (n = 90), (2) a subset of MSI-L CRCs (n = 40), and (3) a subset of probands with MMR-proficient CRC who met Revised Bethesda guidelines, Amsterdam I or II criteria or who had a family history of CRC (n = 35). For MCCS, only probands with MMR deficiency and negative for MLH1 promoter methylation were screened for germline mutations (n = 32). A subset of probands with MLH1 methylation positive CRCs from both studies were tested for germline MMR gene mutations (n = 19). Germline variants were classified for pathogenicity based on the InSiGHT database classifications www.insight-database.org where classes 4 and 5 were considered pathogenic 19 . For variants not yet classified by InSiGHT, we considered a variant as pathogenic if it resulted in a stop codon, frameshift, large deletion, or if it removed a canonical splice site. Individuals with a MMR-deficient CRC, negative for the BRAF V600E mutation and MLH1 promoter methylation, but without an identified MMR gene germline mutation were considered as Lynch-like syndrome cases 20 .
Statistical analysis. Statistical analyses were conducted using SPSS statistics software version 19.0 (SPSS Inc., Chicago, IL, USA). Categorical variables were compared using Fisher's exact test, and continuous variables were compared using non-parametric Wilcoxon-Mann-Whitney rank-sum test. All P-values were two-tailed and P-values less than 0.05 were considered to be statistically significant to test null hypothesis.
Results
Primary CRC tissue (n = 823) was available for molecular characterization from 813 ACCFR probands where MMR deficiency was identified in 94 tumors from 90 probands (11.1%). For the MCCS CRC-affected probands (n = 1046), molecular pathology results were obtained for 851 CRCs from 826 probands (79%). MMR deficiency was identified in the tumors of 103 participants (12.5%). The characteristics of the ACCFR and MCCS study participants overall and by their tumor MMR status are shown in Tables 1 and 2 , respectively. Detail for the patterns of abnormal MMR expression and germline mutations are given in Table 3, Table S1 and in the flow diagrams ( Figs. 1 and 2 ). Methylation of the MLH1 gene promoter was observed in 25% and 85.7% of MLH1/PMS2-deficient CRCs from the ACCFR and MCCS, respectively. Of the MLH1/PMS2-deficient CRCs that were positive for MLH1 methylation, only 61.5% and 77.8% were also positive for the BRAF V600E somatic mutation (ACCFR and MCCS studies, respectively). No pathogenic MLH1 gene mutations were identified out of 10 (ACCFR) and 9 (MCCS) probands with MLH1 methylated CRCs that were tested. MLH1 methylation was not observed in 47 MMR-proficient CRCs tested from the ACCFR.
A MMR gene mutation was identified in 42 ACCFR probands (5.2%), representing 46.5% of the MMR-deficient CRCs. Two of the mutation carriers were identified among individuals with MMR-proficient tumors, both carried MSH6 mutations. None of the 40 ACCFR probands with an MSI-L CRC were found to have a germline MMR gene mutation. Comparing these results to the MCCS findings, only 7 probands had a pathogenic germline mutation (0.8%), representing 5.8% of the MMR-deficient CRCs. Of the 47 non-overlapping MMR gene mutation carriers identified in this study, 13 (27.7%) met Amsterdam I criteria, 4 (8.5%) met Amsterdam II criteria, 26 (55.3%) met Revised Bethesda guidelines and 1 (2.1%) had no clinical family history.
A number of atypical patterns of MMR deficiency were observed across both studies namely, the loss of expression of 3 or more MMR proteins within a single CRC (Table 3) . Four CRCs (all women, diagnosis ages were 59, 73, 75, and 77 years) demonstrated loss of MLH1 and PMS2 as well as loss of MSH6. All four tumors were right-sided, demonstrated MLH1 promoter methylation, the BRAF V600E somatic mutation, and the absence of MLH1 or MSH6 germline mutations. A single CRC demonstrated loss of MSH2 and MSH6 as well as loss of PMS2 expression while retaining MLH1 expression. A germline mutation in PMS2 was identified while no MSH2 or MSH6 germline mutation was identified to account for the loss of MSH2/MSH6 expression. A female MCCS proband developed synchronous ascending colon tumors at promoter hypermethylation and the BRAF V600E somatic mutation; however, no MSH2 or MSH6 germline mutation was identified. One additional MCCS proband developed a MLH1/PMS2 Probands with MMR-deficient CRCs that underwent germline mutation testing but had no pathogenic mutation identified, or had a variant of uncertain significance (VUS) identified or did not show evidence of MLH1 methylation were, therefore, considered suspected Lynch or Lynch-like cases. For the ACCFR 37/90 (41.1%) MMR-deficient CRCs were considered Lynch-like while for the MCCS 26/103 (25.2%) of the MMR-deficient CRCs were considered Lynch-like. The combined Lynch-like syndrome probands from the ACCFR and MCCS had a median age of diagnosis of 50 years which was older than the median age of MMR gene mutation carriers (P = 0.002) and younger than the median age of MMR-proficient cases (P = 0.02) and MLH1 methylation cases (P < 0.001) ( Table 4 ). There was no evidence Tumor testing to identify lynch syndrome DD Buchanan et al. for a difference in the tumor characteristics of MMR gene mutation carriers and Lynch-like syndrome probands ( Table 4) . The combined data from the two cohorts demonstrated that all the mutation carriers identified in this study were diagnosed prior to 70 years of age and that 95.7% of carriers were identified prior to a diagnosis age of 60 years (Table 5) . When considering the group of individuals with MMR-deficient CRCs who were positive for MLH1 methylation and, therefore, would not have germline mutation testing in the clinical setting, 56.5% and 83.5% of all the MLH1 methylated MMR-deficient CRCs were identified in the age at CRC diagnosis groups of > 70 years and > 60 years, respectively. The yield of MMR mutation carriers relative to the number of MMR IHC tests that were performed demonstrated that testing: (1) all CRCs, (2) only those diagnosed < 70 years or (3) those diagnosed < 60 years resulted in yields of 2.9%, 3.7%, and 4.7%, respectively, for a total of 1639, 1267, and 951 MMR IHC tests performed for those same three scenarios.
The sensitivity, specificity, positive, and negative predictive values and positive likelihood ratio for MMR IHC testing overall and by differing age at CRC diagnosis thresholds are shown in Table S2.
Discussion
In this study, we report the results of tumor and germline mutation testing of CRC-affected individuals from two Australian cohorts to identify Lynch syndrome. From the ACCFR, where probands were diagnosed with CRC before age 60, we identified MMR deficiency in 11.1% of cases of which 14.4% were secondary to MLH1 methylation. A MMR gene mutation was identified in 40 probands with a MMR-deficient CRC and in 2 probands with a MMR-proficient CRC for a total prevalence of 5.2%. From the MCCS, where all incident CRCs were recruited from probands aged 41-86, the proportion of MMR deficiency was 12.5% of . Compared with these studies, our study included individuals older than 60 years at CRC diagnosis to address the potential benefit of universal CRC screening by MMR IHC. The results for the detection of Lynch syndrome in the ACCFR were twice as high compared with the Western Australian cohort (5.2% vs 2.6%) where both studies were restricted to investigating CRCs diagnosed before 60 years of age; however, the recruitment of only 50% of patients with CRC diagnosed between the ages of 45-59 years in Phase I of the ACCFR study may have led to some bias in the number of mutation carriers identified.
Interestingly, 3 ACCFR cases with normal MMR IHC expression were MSH6 mutation carriers, although 2/3 did demonstrate high levels of MSI. This is in agreement with previous studies which reported that a substantial proportion of tumors in MSH6 mutation carriers showed low level or absence of MSI and retained IHC expression of MSH6, in particular for missense mutations 21, 22 . These observations and our own findings showing that patients with MSH6 mutations maybe missed by IHC and MSI testing suggests the prevalence of Lynch syndrome caused by MSH6 mutations is probably underestimated in the population.
Most MLH1-deficient CRCs are sporadic, caused by somatic MLH1 promoter methylation. Two molecular genetic tests are currently used to identify these cases: MLH1 promoter methylation and BRAF V600E mutation testing. In our study, BRAF V600E was observed in 61.5% and 77.8% of CRCs positive for MLH1 methylation from the ACCFR and MCCS studies, respectively, suggesting that using BRAF V600E instead of MLH1 methylation as a negative MMR mutation predictor would result in~20%-40% of CRCs with MLH1 and PMS2 loss of protein expression being incorrectly referred for germline mutation testing. However, in most pathology departments, BRAF V600E testing is the most accessible and therefore preferred strategy showing less variability in methodologies with non-quantitative results. Recently, IHC with a specific antibody for the BRAF V600E protein has become available to be used in as a promising surrogate marker for sequencing. However, despite some initial encouraging results, 23 BRAF V600E IHC should be used with caution because of the variable reliability for determining the BRAF V600E status in CRC with sensitivity and specificity as low as 59% and 51%, respectively (reviewed in 24 ) , and the increasing recognition of other BRAF mutations (non V600E) in up to 23% of CRC that would not be identified with this mutation-specific antibody [25] [26] [27] . Universal testing, or reflex testing of all newly diagnosed CRC tumors for MMR protein status, has been recommended or endorsed by several organizations as the preferred approach to identify Lynch syndrome [28] [29] [30] [31] . Universal testing has been shown to reduce morbidity and mortality from Lynch syndrome in relatives 28 . Compared with selective strategies, universal testing is more sensitive to identify Lynch syndrome patients and is cost-effective [32] [33] [34] . In this study, when the results from both cohorts were combined, the number of MMR gene mutation carriers identified peaked in the 41-50 years age group. Based on our data, adopting a universal tumor testing approach compared with a strategy that tested only CRCs diagnosed ≤ 60 years would result in 688 additional MMR IHC tests and 65 additional MLH1 methylation tests for the identification of two mutation carriers. An upper age threshold of 70 years would mean 372 fewer MMR IHC tests and 57 fewer MLH1 methylation tests for no gains in identified mutation carriers. The use of upper age cutoffs to limit the testing of older CRC patients who are less likely to have Lynch syndrome has received support 35 . Although the study by Moreira and colleagues 36 found that universal testing was the most sensitive, a model where all CRC diagnosed < 70 years and only those CRCs diagnosed > 70 years that met Bethesda guidelines were tested resulted in a sensitivity of 95.1% (vs 100% sensitivity for universal MMR IHC) with~35% fewer MMR IHC tests being performed.
In the latest 2012 edition of the Cancer Protocol for CRC, recommendation from the Royal College of Pathologists of Australasia is to perform IHC for MMR protein expression in all CRC cases diagnosed in patients less than 50 years of age and in patients meeting the revised Bethesda criteria 37 . Despite low Tumor testing to identify lynch syndrome DD Buchanan et al.
numbers of identified Lynch syndrome in individuals older than 50 years, our findings suggest that the Royal College of Pathologists of Australasia could increase their age limit recommendations to test all CRCs diagnosed < 70 years of age, and be performed in conjunction with MLH1 promoter methylation or BRAF V600E mutation testing for MLH1-deficient CRCs, as the optimal strategy to identify MMR gene mutation carriers. A cost-effectiveness study in Australia would be useful to support this suggestion. If laboratory resources are limited, MMR IHC tumor testing of all CRC cases diagnosed ≤ 60 years of age in conjunction with MLH1 promoter methylation testing would also be an efficient strategy, although less sensitive and has been recommended for Lynch syndrome screening in endometrial cancer 16 .
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